

Experience of MTZ Clinical Research in Bioequivalence studies

Lp.	Therapeutic /Chemical subgroup	Chemical substance	Population
Alimentary tract and metabolism			
1	Drugs used in diabetes	Glimepiride	Healthy subjects
2	Lipid modifying agents	Lovastatin	Healthy subjects
3	Lipid modifying agents	Rosuvastatin	Healthy subjects
4	Lipid modifying agents	Rosuvastatin	Healthy subjects
5	Lipid modifying agents	Simvastatin	Healthy subjects
Antiinfectives for systemic use			
6	Antibacterials for systemic use	Azithromycin	Healthy subjects
7	Antibacterials for systemic use	Azithromycin	Healthy subjects
8	Antibacterials for systemic use	Azithromycin	Healthy subjects
9	Antivirals for systemic use	Oseltamivir	Healthy subjects
10	Antivirals for systemic use	Aciclovir	Healthy subjects
Antineoplastic and immunomodulating agents			
11	Antineoplastic agents	Capecitabine	Healthy subjects
12	Antineoplastic agents	Capecitabine	Metastatic Solid Tumors
13	Antineoplastic agents	Capecitabine	Metastatic Solid Tumors
14	Antineoplastic agents	Capecitabine	Healthy subjects
15	Antineoplastic agents	Capecitabine	Healthy subjects
16	Antineoplastic agents	Doxorubicin Hydrochloride Liposome	Advanced Carcinoma of the Ovary
17	Taxane	Paclitaxel	Metastatic breast cancer
Blood and blood forming organs			
18	Antithrombotic agents	Acetylsalicylic Acid	Healthy subjects
Cardiovascular system			
19	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
20	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
21	Agents acting on the renin-angiotensin system	Lisinopril	Healthy subjects
22	Calcium channel blockers	Nitrendypine	Healthy subjects
23	Calcium channel blockers	Nicardipine hydrochloride	Healthy subjects
24	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects
25	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects
26	Cardiac therapy	Isosorbide-5-mononitrate	Healthy subjects
27	Diuretics	Indapamide	Healthy subjects
28	Diuretics	Indapamide	Healthy subjects
29	Lipid modifying agents	Simvastatin	Healthy subjects
30	Vasoprotectives	Calcium dobesilate	Healthy subjects

Experience of MTZ Clinical Research

Early Clinical Development

Lp.	Therapeutic /Chemical subgroup	Chemical substance	Population
Dermatologicals			
31	Antipsoriatics	Tacalcitol	Plaque Psoriasis
32	Antipsoriatics	Tacalcitol	Plaque Psoriasis
33	Corticosteroids	Mometasone furoate	Healthy subjects
34	Corticosteroids	Mometasone furoate	Healthy subjects
35	Corticosteroids	Mometasone furoate	Healthy subjects
36	Corticosteroids	Mometasone furoate	Healthy subjects
37	Corticosteroids	Betamethasone dipropionate	Healthy subjects
38	Corticosteroids	Betamethasone dipropionate and salicylic acid	Healthy subjects
39	Corticosteroids	Betamethasone dipropionate and salicylic acid	Healthy subjects
40	Corticosteroids	Betamethasone dipropionate and gentamicin sulfate	Healthy subjects
41	Corticosteroids	Betamethasone dipropionate and gentamicin sulfate	Healthy subjects
42	Flavonoid	Genistein	Healthy subjects
Genito-urinary system and sex hormones			
43	Sex hormones and modulators of the genital system	Megestrol	Healthy subjects
44	Sex hormones and modulators of the genital system	Megestrol	Healthy subjects
Musculo-skeletal system			
45	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects
46	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects
47	Antiinflammatory and antirheumatic products	Ibuprofen	Healthy subjects
48	Anti-inflammatory and antirheumatic products	Ibuprofen	Healthy subjects
49	Antiinflammatory and antirheumatic products	Naproxen	Healthy subjects
50	Drugs for treatment of bone diseases	Alendronic acid	Healthy subjects
51	Drugs for treatment of bone diseases	Risedronic acid	Healthy subjects
52	Muscle relaxants	Thiocolchicoside	Healthy subjects
Nervous system			
53	Antiepileptics	Lamotrigine	Healthy subjects
54	Antiepileptics	Pregabalin	Healthy subjects
55	Antiepileptics	Topiramate	Healthy subjects
56	Antiepileptics	Topiramate	Healthy subjects
57	Antivertigo preparations	Cinnarazinum & Dimenhydrinatum	Healthy subjects
58	Other nervous system drugs	Betahistine	Healthy subjects
59	Psychoanaleptics	Amitriptyline	Healthy subjects
60	Psychoanaleptics	Amitriptyline	Healthy subjects
61	Psychoanaleptics	Aniracetam	Healthy subjects
62	Psychoanaleptics	Memantine	Healthy subjects
63	Psychoanaleptics	Mirtazapine	Healthy subjects
64	Psychoanaleptics	Rasagiline	Healthy subjects

Date of issue: May 2019

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Early Clinical Development

Lp.	Therapeutic /Chemical subgroup	Chemical substance	Population
65	Psychoanaleptics	Trazodone	Healthy subjects
66	Psycholeptics	Olanzapine	Healthy subjects
	Respiratory system		
67	Antihistamines	Clemastine	Healthy subjects
68	Antihistamines	Levocetirizine	Healthy subjects
69	Antihistamines	Loratadine	Healthy subjects
70	Drugs for obstructive airway diseases	Fluticasone propionate / salmeterol	Healthy subjects
71	Drugs for obstructive airway diseases	Mometasone furoate	Healthy subjects
72	Drugs for obstructive airway diseases	Mometasone furoate	Healthy subjects
73	Nasal preparations	Fluticasone furoate	Healthy subjects
	Various		
74	Antiinflammatory / Sympathomimetics	Ibuprofen / Pseudoephedrine	Healthy subjects
75	Antiinflammatory / Sympathomimetics	Ibuprofen / Pseudoephedrine	Healthy subjects

Date of issue: May 2019

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN

